Clinical Trials Directory

Trials / Completed

CompletedNCT00361920

Cell Biology of Steroid Resistant Asthma

Investigating Biomarkers of Steroid Resistant Asthma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
National Jewish Health · Academic / Other
Sex
All
Age
12 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The hypothesis is that patients who demonstrate steroid resistant asthma by showing little or no improvement in lung function after a course of oral steroids have different cellular responses to steroids than patients who are steroid sensitive. These altered responses are the reason they demonstrate steroid resistance.

Detailed description

Current NHLBI guidelines for persistent asthma management recommends the use of steroids for treatment of airway inflammation (1,2). However, some asthmatics do not respond to steroids (3-6). Unfortunately these patients are subjected to the unwanted side effects (osteoporosis, cataracts, etc) of high dose steroid therapy because non-immune tissues remain sensitive to steroids. Recent studies suggest that the costs of asthma are largely attributable to uncontrolled disease (7). Thus, it is important to understand the mechanism(s) of steroid resistance and introduce new forms of therapy for the treatment of these difficult to control asthmatics. As a prelude to pharmaceutical studies in steroid resistant asthma, it is imperative to develop biomarkers that can robustly identify individuals likely to be poor steroid responders so that alternative non-steroid anti-inflammatory therapies, such as Xolair®, can be introduced early in the course of asthma therapy.

Conditions

Interventions

TypeNameDescription
DRUGprednisone

Timeline

Start date
2006-08-01
Primary completion
2007-03-01
Completion
2007-03-01
First posted
2006-08-09
Last updated
2017-03-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00361920. Inclusion in this directory is not an endorsement.